BSE and NSE Fine Bliss GVS Pharma for Board Composition Non-Compliance
Bliss GVS Pharma Ltd 路 Others (Uncategorized) 路 06 Nov 2026, 9:20 pm
BSE and NSE Fine Bliss GVS Pharma for Board Composition Non-Compliance BSE and NSE have each levied a fine of Rs. 1,80,000 (excluding GST) on Bliss GVS Pharma Ltd. for non-compliance with Regulation 17(1) of SEBI Listing Regulations, specifically regarding board composition and failure to appoint a woman director. The orders, received on 25th Aug'26, represent approximately 0.000269% of the company's market capitalisation. Bliss GVS Pharma confirmed that the penalties have been fully paid, with no material impact on operations or financials beyond the stated fine amounts.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... 路 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 29 Oct 2026
